Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site

Valuation: Vanda Pharmaceuticals Inc.

Capitalization 300M 285M 265M 236M 421M 25.4B 461M 3.28B 1.22B 10.42B 1.13B 1.1B 45.19B P/E ratio 2024 *
-16.3x
P/E ratio 2025 * 137x
Enterprise value 111M 106M 98.22M 87.67M 156M 9.42B 171M 1.22B 453M 3.86B 418M 409M 16.76B EV / Sales 2024 *
0.56x
EV / Sales 2025 * 1.34x
Free-Float
96.85%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.77%
1 week+1.18%
1 month+10.52%
3 months-2.65%
6 months+0.78%
Current year+22.04%
More quotes
1 week
4.88
Extreme 4.88
5.42
1 month
4.65
Extreme 4.65
5.55
Current year
3.46
Extreme 3.46
6.75
1 year
3.46
Extreme 3.46
6.75
3 years
3.30
Extreme 3.295
18.00
5 years
3.30
Extreme 3.295
21.86
10 years
3.30
Extreme 3.295
33.44
More quotes
Director TitleAgeSince
Chief Executive Officer 64 2003-04-30
Director of Finance/CFO 40 2020-03-14
Human Resources Officer - 2019-07-31
Manager TitleAgeSince
Chairman 64 -
Director/Board Member 82 2005-11-30
Director/Board Member 44 2019-04-23
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.77%+1.18%+32.05%-67.71%300M
+0.77%+3.81%+33.31%+128.36%121B
-0.62%+1.66%-7.93%+18.97%80.72B
-0.74%+0.65%+40.52%+134.65%37.35B
-1.93%+4.65%+19.10%-64.60%28.38B
+4.29%+12.85%+14.67%-38.92%22.84B
+1.50%+1.03%-39.59%-65.73%19.65B
+0.99%+2.86%-29.29%-40.32%13.72B
-2.53%-2.84%+766.67%+276.73%13.61B
-0.95%+2.75%+183.41%+181.60%13.45B
Average +0.00%+2.97%+101.29%+46.30% 35.06B
Weighted average by Cap. +0.15%+3.20%+49.91%+67.48%
See all sector performances

Financials

2024 *2025 *
Net sales 198M 188M 175M 156M 278M 16.76B 304M 2.16B 806M 6.88B 745M 728M 29.83B 272M 258M 240M 214M 381M 22.99B 417M 2.97B 1.1B 9.43B 1.02B 998M 40.9B
Net income -18.72M -17.74M -16.51M -14.73M -26.23M -1.58B -28.75M -204M -76.11M -649M -70.33M -68.77M -2.82B 4.57M 4.33M 4.03M 3.6M 6.4M 386M 7.01M 49.87M 18.57M 158M 17.16M 16.78M 687M
Net Debt -189M -179M -167M -149M -265M -15.98B -290M -2.06B -768M -6.55B -710M -694M -28.43B 65.1M 61.7M 57.41M 51.24M 91.21M 5.51B 99.96M 711M 265M 2.26B 245M 239M 9.8B
More financial data * Estimated data
Logo Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Employees
203
More about the company
Date Price Change Volume
24-11-29 5.150 $ -0.77% 264,859
24-11-27 5.190 $ +4.22% 833,924
24-11-26 4.980 $ -1.39% 529,323
24-11-25 5.050 $ -0.79% 487,097

Delayed Quote Nasdaq, November 29, 2024 at 01:00 pm EST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C-
surperformance-ratings-light-chart VANDA-PHARMACEUTICALS-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
5.150USD
Average target price
10.43USD
Spread / Average Target
+102.48%
Consensus

Quarterly revenue - Rate of surprise

Exceptional Extension | BLACK FRIDAY -40% : Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW